Search

ENPNewswire-April 28, 2023--Ovid Therapeutics Inc. - Long-term Safety and Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting (C)2023 ENPublishing - [...]

(EDGAR Online via COMTEX) -- 0001636651false00016366512023-04-272023-04-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

Cambridge: AstraZeneca PLC (AZNCF) has issued the following press release: Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis' [...]

SOUTH SAN FRANCISCO: Genentech has issued the following news release: Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), is announcing three new partnerships focused on improving [...]

PHILADELPHIA, PA -- The following information was released by the University of Pennsylvania School of Medicine: Virginia M.Y. Lee, PhD and Roy H. Hamilton, MD, MS, are recognized for their [...]

ENPNewswire-April 26, 2023--TG Therapeutics Announces Presentation of Data from the ULTIMATE I and II Phase 3 Trials of BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 75th Annual [...]

ENPNewswire-April 26, 2023--ProMIS Neurosciences Inc. - Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's disease (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 25042023 - [...]

Fosgonimeton improves MMSE (mini-mental state evaluation) after six months in a post hoc analysis from the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer's disease Preclinical findings with fosgonimeton further elucidate [...]

NEW YORK: Axsome Therapeutics, Inc. has issued the following news release: Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous [...]

* PROOF-HD primary endpoint (Unified Huntington Disease Rating Scale-Total Functional Capacity) and the key secondary endpoint (Composite Unified Huntington's Disease Rating Scale) did not reach statistical significance * PROOF-HD marks [...]

M2 PRESSWIRE-April 25, 2023-: NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks [...]

ENPNewswire-April 25, 2023--Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 24042023 - [...]

ENPNewswire-April 25, 2023--Ionis Pharmaceuticals - Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks (C)2023 ENPublishing - http://www.enpublishing.co.uk Release [...]

ENPNewswire-April 25, 2023--Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data across Neuroscience Medicines at AAN 2023 Annual Meeting (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 24042023 - South San [...]

ENPNewswire-April 25, 2023--Astrazeneca - NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks [...]

ENPNewswire-April 25, 2023--ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting (C)2023 ENPublishing - http://www.enpublishing.co.uk Release [...]

SAN DIEGO: Amprion has issued the following news release: Amprion is pleased to announce that it will attend the American Academy of Neurology (AAN) Annual Meeting in Boston April 22-27 [...]

(EDGAR Online via COMTEX) -- false0000874015NASDAQ00008740152023-04-242023-04-24 -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF [...]

Lead therapeutic candidate for Alzheimer's disease, PMN310, demonstrate d selective binding and protection against toxic amyloid-beta oligomers Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP [...]

SAN FRANCISCO: Neurona Therapeutics has issued the following news release: Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of [...]

SAN FRANCISCO: Verana Health has issued the following news release: Verana Health(r)--a digital health company elevating quality in real-world data (RWD)--today announced it's releasing in Q2 2023 a Qdata(r) module [...]

WILMINGTON, Del.--(BUSINESS WIRE)--Apr 24, 2023-- Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all co-primary endpoints [...]

-- Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis, and telehealth initiatives to assess & address deterrents to brain health to better understand holistic health [...]

Eplontersen halted neuropathy disease progression and improved neuropathy impairment and quality of life WILMINGTON, Del. -- Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid [...]

ENPNewswire-April 24, 2023--Verana Health Announces the Qdata Parkinson's Disease Module at 2023 AAN Annual Meeting (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 21042023 - SAN FRANCISCO - Verana Health-a digital health [...]

An oral presentation will highlight findings related to Amprion's ðSyn Seed Amplification Assay and its validation within the landmark Parkinson's Progression Markers Initiative (PPMI) study Amprion leaders will be on [...]

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, [...]

Neurology Qdata Module Will Provide Real-World Evidence from De-Identified Parkinson's Patients in American Academy of Neurology's Axon Registry SAN FRANCISCO, April 21, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3843418-1&h=112798974&u=https%3A%2F%2Fwww.veranahealth.com%2F&a=Verana+Health -a digital health company [...]

The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previously failed two to four classes of conventional oral [...]

BOSTON: Praxis Precision Medicines, Inc. has issued the following news release: Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for [...]

SAN MATEO: Cala, the bioelectronic medicine leader setting a new standard of patient care for chronic disease, will preview the next generation of its wearable neuromodulation system and the results [...]

The ALITHIOS open-label extension study showed continuous treatment with Kesimpta(ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of disability progression versus [...]

(GLOBE NEWSWIRE via COMTEX) -- - The ALITHIOS open-label extension study showed continuous treatment with Kesimpta(R) (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated [...]

FRAMINGHAM: Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer's disease (AD) and other neurodegenerative disorders, will be [...]

ENPNewswire-April 19, 2023--Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 and Results of Phase 2 Biomarker Study at American Academy of Neurology [...]

CARSON CITY: BioVie, Inc. has issued the following news release: BioVie Inc. (NASDAQ: BIVI) ('BioVie' or the 'Company'), a clinical-stage company developing innovative drug therapies for the treatment of neurological [...]

DEERFIELD: LUNDBECK has issued the following news release: Lundbeck today announced new neuroscience data will be presented at the 75th Annual Meeting of the American Academy of Neurology taking place [...]

Alzheimer's Disease (AD) Patients with APOE4/4 Homozygous Genotype Show More Frequent Cerebral Amyloid Angiopathy (CAA) Lesions at Baseline CAA Pathology Increases Risk of Treatment-Induced Brain Edema and Hemorrhage with Anti-Amyloid [...]

* Breadth of data showcases Lundbeck's commitment to advancing neuroscience * New clinical and real-world evidence supporting VYEPTI as a preventive migraine treatment in adults; medical symposium to feature interactive, [...]

Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer's disease patients including improvements in measures of cognition and plasma biomarkers Oral presentation [...]

BOSTON: Aisa Pharma has issued the following news release: Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company, today announced it will present data on its clinical drug candidate, Profervia(r) at [...]

ENPNewswire-April 4, 2023--AISA Pharma Announces Upcoming Profervia Data Presentations at AAN and EULAR (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 03042023 - Boston - Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical [...]

Profervia impact on key Nav 1.7 pain channel to be presented at AAN Initial Positive Phase 2 data from RECONNOITER-1 Trial in Systemic Sclerosis patients with Raynaud's Phenomenon to be [...]

ENPNewswire-March 31, 2023--Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA Trial at AAN Annual Meeting [...]

San Francisco -- The following information was released by the University of California, San Francisco: American Academy of Neurology to Honor Jon Kleen, MD, PhD By Melinda Krigel Jon Kleen, [...]

GENOA: IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, [...]

ENPNewswire-March 14, 2023--ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 13032023 - TORONTO - ProMIS Neurosciences [...]

GENOA, Italy -- IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from [...]